Timothée Olivier: The regulatory failure of sotorasib in lung!
Timothée Olivier, Medical Oncologist at HUG – Geneva University Hospitals shared a thread on X:
“Out in The Lancet Oncology!
Led by Sruthi Ranganathan with Vinay Prasad, we reviewed the regulatory failure of sotorasib in lung!
-points we made right after ESMO22
-the FDA sensitivity analyses
-our additionnal concerns about OS
-future measures
Check the Reviewed paper here.
Future measures to avoid such failure?
1. double-blind (decreased risk of informative censoring)
2. Overall Survival instead of Progression Free Survival (at least) in poor prognosis settings
3. real-time Blinded Independent Centrak Review (BICR) (quick detection of any not equal to with investigators)
4. long-term survival Follow Up of censored patients
5. real data-sharing
Check out the full paper here.
The story is still ongoing…FDA Oncology, EU Medicine Agency News, Swissmedic.
Thanks for following our works VK Prasad Lab.”
Source: Timothée Olivier/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023